Taysha Gene Therapies
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $1,788 | $1,112 | $3,411 | $3,604 |
Gross Profit | 1,788 | 812 | 3,086 | 3,238 |
EBITDA | -25,200 | -20,601 | -23,707 | -15,431 |
EBIT | -25,494 | -20,901 | -24,032 | -15,797 |
Net Income | -25,524 | -20,928 | -24,061 | 47,741 |
Net Change In Cash | 1,788 | 1,112 | 3,411 | 3,604 |
Free Cash Flow | -21,650 | -21,705 | -19,956 | -16,134 |
Cash | 157,688 | 172,743 | 124,429 | 144,389 |
Basic Shares | 267,824 | 232,821 | 231,249 | 186,960 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $15,451 | $2,502 | $0 | $0 |
Gross Profit | 14,080 | 15 | -492 | -9 |
EBITDA | -105,197 | -159,729 | -172,775 | -42,993 |
EBIT | -106,568 | -162,216 | -173,267 | -43,002 |
Net Income | -111,566 | -169,581 | -175,459 | -43,000 |
Net Change In Cash | 15,451 | 2,502 | 0 | 0 |
Cost of Revenue | 251,253 | |||
Free Cash Flow | -80,387 | -113,259 | -138,596 | -39,811 |
Cash | 143,940 | 87,880 | 149,103 | 251,253 |
Basic Shares | 116,121 | 43,952 | 37,650 | 17,665 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.07 |
2024-06-30 | -$0.09 |
2024-03-31 | -$0.10 |
2023-12-31 | $0.92 |
